<DOC>
	<DOCNO>NCT02083536</DOCNO>
	<brief_summary>The ultimate clinical aim propose phase I trial evaluate toxicity determine recommend phase II dose combine effect LDFWART follow administration docetaxel 6 cycle patient recurrent platinum-resistant ovarian cancer .</brief_summary>
	<brief_title>LDFWART With Docetaxel Patients With Platinum-Resistant Recurrent Ovarian Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Patients must platinumresistant disease relapse within 6 month less date last cycle initial adjuvant chemotherapy recurrent adenocarcinoma primary ovarian , tubal , peritoneal cancer follow firstline chemotherapy metastatic disease . There limit prior number chemotherapy regimen . Patients receive prior systemic docetaxel platinumbased chemotherapy eligible 1.1 Patients must ≥ 1cm measurable disease image study independent patient optional surgical salvage procedure . 2 . Patients must life expectancy least 6 month . 3 . Patients must Karnofsky performance status ≥ 60 Gynecology Oncology ( GOG ) performance status ≤ 2 ( see www.GOG.org website ) . 4 . Age 18 80 year old 5 . Patients must adequate bone marrow , renal , hepatic function : 5.1 WBC : ≥ 3,000 /mcl 5.2 ANC : ≥ 1,500 /mcl 5.3 Platelets : ≥ 100,000 /mcl 5.4 Creatinine : &lt; 2.0 mg/dcl 5.5 Bilirubin : &lt; 1.5x institutional normal value 5.6 LDH , GGT , SGPT ( ALT ) , SGOT ( AST ) , ALK Phos : &lt; 3x institutional normal value . 6 . Ability understand willingness sign write informed consent document . 1 . Patients receive prior radiotherapy chest , whole abdomen , low extremity knee . 2 . Patients receive prior radiation therapy head , neck , low extremity knee great 3 year prior study entry . 3 . Evidence extraabdominal extension disease ( groin node , lung , supraclavicular node , pleural fluid ) . 4 . Patients may receive investigational agent within 4 week precede start study treatment ) chemotherapy least 3 week precede start study treatment . 5 . Patients diagnose another prior malignant tumor within 3 year study entry , exclude nonmelanoma skin cancer carcinoma situ cervix . 6 . Patients prior history severe hypersensitivity reaction paclitaxel ( polysorbate 80Cremophor ) . 7 . Patients current history uncontrolled hypertension , angina pectoris , heart failure , cardiac dysrhythmias , pericardial disease , cardiomyopathy , active infection . 8 . Presence medical condition opinion investigator deem patient unable participate . 9 . Females childbearing potential . It expect ovarian cancer patient would hysterectomy and/or oophorectomy part original standard care . 10 . Patients &lt; 18 yr . age &gt; 80 yr . age .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Low Dose Fractionated Whole Abdominal Radiation Therapy</keyword>
	<keyword>LDFWART</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Ovarian Carcinoma</keyword>
	<keyword>Platinum-Resistant</keyword>
</DOC>